rabbit anti nlgn2 (Bioss)
Bioss is a verified supplier 
Bioss manufactures this product 
91
Structured Review
Bioss
rabbit anti nlgn2
Rabbit Anti Nlgn2, supplied by Bioss, used in various techniques. Bioz Stars score: 91/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti nlgn2/product/Bioss
Average 91 stars, based on 2 article reviews
Rabbit Anti Nlgn2, supplied by Bioss, used in various techniques. Bioz Stars score: 91/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti nlgn2/product/Bioss
Average 91 stars, based on 2 article reviews
rabbit anti nlgn2 - by Bioz Stars,
2026-02
91/100 stars
Images
1) Product Images from "Clinical Relevance and Prognostic Value of the Neuronal Protein Neuroligin 2 in Breast Cancer"
Article Title: Clinical Relevance and Prognostic Value of the Neuronal Protein Neuroligin 2 in Breast Cancer
Journal: Frontiers in Oncology
doi: 10.3389/fonc.2021.630257
Figure Legend Snippet: NLGN2 is a prognostic factor of breast cancer. (A) Prognostic analysis of NLGN2 in breast cancer. (B) Prognostic analysis of NLGN2 in post-treated breast cancer. (C) Prognostic analysis of NLGN2 in basal breast cancer. (D) Prognostic analysis of NLGN2 in luminal A breast cancer. (E) Prognostic analysis of NLGN2 in luminal B breast cancer. (F) Prognostic analysis of NLGN2 in HER2+ breast cancer. The HR and log rank p values are indicated in each panel, and p < 0.05 is statistically significant.
Techniques Used:
Figure Legend Snippet: NLGN2 is favorable for HER2- breast cancer patients. (A) Prognostic analysis of NLGN2 in ER- breast cancer. (B) Prognostic analysis of NLGN2 in PR- breast cancer. (C) Prognostic analysis of NLGN2 in HER2- breast cancer. (D) Prognostic analysis of NLGN2 in ER-/PR-/HER2- breast cancer. (E) Prognostic analysis of NLGN2 in TP53 wild type breast cancer. (F) Prognostic analysis of NLGN2 in TP53 mutated breast cancer. The HR and log rank p values are indicated in each panel, and p < 0.05 is statistically significant.
Techniques Used:
Figure Legend Snippet: NLGN2 is favorable in lymph node non-metastatic breast cancer patients. (A) Prognostic analysis of NLGN2 in lymph node- breast cancer. (B) Prognostic analysis of NLGN2 in lymph node+ breast cancer. (C) Prognostic analysis of NLGN2 in Grade 1 breast cancer. (D) Prognostic analysis of NLGN2 in Grade 2 breast cancer. (E) Prognostic analysis of NLGN2 in Grade 3 breast cancer. The HR and log rank p values are indicated in each panel, and p < 0.05 is statistically significant.
Techniques Used:
Figure Legend Snippet: NLGN2 correlates with immune signatures in breast tumor. (A) Correlation analysis of NLGN2 and IFNG in breast cancer (BRCA). (B) Correlation analysis of NLGN2 and GZMB in BRCA. (C) Correlation analysis of NLGN2 and Cytotoxic T cell signatures in BRCA. (D) Correlation analysis of NLGN2 and Helper T cell signatures in BRCA. (E) Correlation analysis of NLGN2 and B cell signatures in BRCA. (F) Correlation analysis of NLGN2 and Macrophage cell signatures in BRCA. (G) Correlation analysis of NLGN2 and NK cell signatures in BRCA. (H) Correlation analysis of NLGN2 and Dendritic cell signatures in BRCA. The p values and R coefficient are indicated in each panel, and p < 0.05 is statistically significant.
Techniques Used:
Figure Legend Snippet: Association of the expression levels of NLGN2, CD3 and CD8 in breast cancer. Representative images of immunohistochemical staining showing in situ expression of NLGN2, CD3 and CD8 in breast cancer tissue specimens. Left panels, low expression of NLGN2 in breast tumor tissue, and CD3+ and CD8+ T cells in the same tissue. Right panels, high expression of NLGN2 in breast tumor tissue, and CD3+ and CD8+ T cells in the same tissue. The arrows point to CD3+ or CD8+ lymphocytes. All photos are at 400× original magnification.
Techniques Used: Expressing, Immunohistochemical staining, Staining, In Situ
Figure Legend Snippet: The relationship between NLGN2 expression and the clinicopathological features of breast cancer patients.
Techniques Used: Expressing
Figure Legend Snippet: The relationship between NLGN2 expression and CD3+ and CD8+ tumor infiltrating lymphocytes.
Techniques Used: Expressing
Figure Legend Snippet: NLGN2 is localized in the mitochondria of multiple cancer and normal cells. (A–D) Representative immunofluorescence images showing NLGN2 localization in (A) MCF7 breast adenocarcinoma cells, (B) U2OS osteosarcoma cells, (C) U251MG glioblastoma cells, and (D) NIH3T3 mouse embryonic fibroblast cells. Green: NLGN2; Blue: Nucleus.
Techniques Used: Immunofluorescence